683 / 1068
Statement – CRT and Oxaliplatin?
•
The rationale to add oxaliplatin (and other concurrent
systemic agents) to CRT for rectal cancer is
not
primarily for radiosensitization, pCR, or even local
control (
– unless organ preservation is attempted
).
•
The most important objective is to improve DFS/OS